The application of STI571 in patients with chronic myelogenous leukemia treated before allogenic peripheral blood stem cell transplantation

Objective:To observe the application of STI571 in patients with accelerated phase of chronic myelocytic leukemia treated before allogeneic peripheral blood stem cell transplantation.Method:bcr/abl gene were examined in patients with CML treated with STI571 at the different time points by means of the qualitative reverse transcription polymerase chain reaction (RT-PCR) technique, and the bone morphology and chromosome were analysised simultaneously.Result:①Before Allo-PBSCT, two patients were treated with STI571, and two cases obtained complete hematopoietic remission and one of them obtained complete cytogenetic remission. ②After transplanstation, neutrophil cell 0.5×10 9/L, platelet20×10 9/L in two cases were 13 day and 20 day. ③The blood type of one case changed to donor's in +32 day, the other case had stable engraftment and donor chimerism in +40 day.Conclusion:Bcr/abl positive primitive stem cells in G0 phrase may go into cell cycle after chemotherapy and the cells in cell cycle were sensitive to STI571. It is helpful to purge the bcr/abl positive leukemia cells when CML patients, especially those in accelerated phase and blast crisis are treated with STI571 before PBSCT.